HeartWare remains well positioned in LVAD market, says Leerink Leerink attributes HeartWare's (HTWR) disappointing Q4 sales to company-specific issues and broader market weakness. The firm expects competitor Thoratec (THOR) to trade lower on the potential for LVAD market weakness, but keeps Outperform ratings on companies. Leerink still views Thoratec as well positioned in the LVAD market and sees potential catalysts in 2014.
News For HTWR;THOR From The Last 14 Days
Check below for free stories on HTWR;THOR the last two weeks.